Hydrogel Bioinks in 3D Bioprinting: Key Properties and Types

Creating functional vasculature is essential for viable large-scale engineered tissues. Sacrificial bioprinting deposits sacrificial fibers that template hollow channels, which are then removed to create perfusable pathways. Endothelial cells can line these channels, forming tight junctions that regulate molecule diffusion—slowing transport compared to empty channels. This creates physiologically accurate barriers. The technology enables modeling of thrombosis, where blood clots form within printed vessels, and diffusion-dependent drug effects that cannot be captured by 2D cultures.

Bioprinting capabilities extend beyond simple layered models to complex vascularized constructs addressing fundamental engineering challenges. Simple models replicate basic skin architecture with fibroblast and keratinocyte layers, suitable for basic research and compound testing. More advanced applications require vascularization to overcome oxygen and nutrient diffusion limitations in thicker tissues. The sacrificial material technique enables channel creation: PEG is printed as a hollow tube, surrounded by cross-linked bioink, then liquefied and aspirated to leave a perfusable channel. Perfusion systems connect these channels to pumps delivering culture media or cell suspensions. This approach maintains viability throughout large constructs and enables endothelial cell seeding to form vessel walls, creating more sophisticated tissue constructs that better approximate native organ physiology.

Traditional tissue engineering struggles with vascularization because thick tissues cannot receive adequate oxygen and nutrients diffusively. Without internal vasculature, cells within 12 hours die from hypoxia. Embedded bioprinting enables creation of branched channel networks connecting single inlets to outlets, allowing perfusion that maintains full-thickness tissue viability for extended periods.

Creating functional vasculature within bioprinted tissues is essential for maintaining cell viability in thick constructs. The approach involves printing fugitive inks that form channel networks, which are then flushed out after printing to leave behind open channels. These channels can be lined with endothelial cells to create blood vessel-like structures or populated with specific cell types (such as proximal tubule cells for kidney tissue) to create organ-specific mimics. This vascularization enables nutrient perfusion necessary for long-term cell survival in engineered tissues.

Creating significantly sized engineered tissues requires perfusable vascular networks from the beginning of culture, otherwise cells die and necrotic regions form. Traditional bioprinting methods (FDM, inkjet, stereolithography) lack sufficient resolution for microvascularization. Organ-on-a-chip approaches face limitations with plastic membranes dividing compartments and flow only guided around rather than through 3D cultures. Sugar-based sacrificial scaffolds were introduced in 2012, where 3D printed sugar structures dissolve to create channels, but they suffer from low resolution, direct dissolution in aqueous matrices requiring post-processing, hygroscopic properties preventing storage, and osmotic pressure issues.

This section covers methods for assessing cell viability after bioprinting and the challenges researchers face. The MTT assay measures metabolic activity as an indicator of cell health. Fluorescent staining (such as with calcein-AM) distinguishes live cells (green fluorescence) from dead cells. Confocal microscopy allows for three-dimensional visualization and cell counting. The section also addresses the challenge of cell adaptation—cells may become too comfortable in their environment and fail to develop properly. Researchers must apply appropriate stress to encourage proper development. The section emphasizes that starting with more cells than needed is common practice, as some cell death is expected throughout the process.

Confirming cell viability is essential when working with bioprinted tissues. Modified viability assays optimized for 3D tissues include: (1) Calcium amine propyl iodide assay - fluorescent stain where living cells appear green and dead cells appear red, allowing quantification of cell viability percentage; (2) LDH (lactate dehydrogenase) assay - measures release of lactate dehydrogenase from dead cells into surrounding media, with more release indicating more dead cells; (3) Alamar blue assay - living cells reduce resazurin into fluorescent form released into media, with high signal reflecting high viability. The LDH and Alamar blue assays can be multiplexed to measure dead cells and healthy cells simultaneously, providing relative measures of cell viability in high-throughput plate-based formats.

Commercially available staining kits can assess cell viability in bioprinted constructs. Live cells stain green while dead cells stain red. This quick assessment ensures that cells have survived the printing and initial culture phases, which is essential before proceeding with further experiments or treatments.

To accelerate development of new bioinks including extracellular matrices for 3D bioprinting, high throughput methods were developed to evaluate new compositions for their potential to 3D bioprint cell-laden structures effectively and reliably. Studies investigated droplets with 1000 cells and 10,000 cells corresponding to cell densities of 10^5 and 10^6 cells per milliliter. Collagen and gelatin based bioinks exhibited higher cell viability by day 7 compared to hyaluronic acid and alginate based bioinks.

Cell survival in bioprinting is assessed using Live/Dead staining (calcein for viable cells, propidium iodide for non-viable cells) with inverted microscopy. Advanced characterization includes immunohistochemistry for protein detection and analysis of extracellular matrix production. These techniques evaluate cell differentiation, matrix production, and overall tissue quality in engineered constructs.

4D printing of hydrogels involves creating three-dimensional structures that can reversibly change shape or properties in response to external stimuli such as temperature, pH, light, or ionic strength. This technology combines hydrogel synthesis with additive manufacturing, where stimuli-responsive hydrogels are printed layer-by-layer and programmed to exhibit specific behaviors through controlled cross-linking gradients, material composition, and spatial arrangement. Applications include smart sensors, actuators, architectural cooling systems, and biomedical devices, representing an emerging interdisciplinary field at the intersection of materials science, engineering, and biotechnology.

Effective 4D biofabrication requires stimuli-responsive materials (hydrogels, shape memory polymers) that are biocompatible, biodegradable, and safe for cells. Four approaches achieve shape transformation: (1) Calcium-triggered unfolding using hyaluronic acid/gelatin bilayers where crosslink density gradients cause tube formation; (2) UV-crosslinkable polymer dissolution where organic solvents remove non-crosslinked polycaprolactone, allowing gelatin swelling to form tubes at 57°C; (3) Thermoplastic melting where polycaprolactone softens at elevated temperatures, enabling gelatin deformation; (4) Shape memory programming where components with varying photosensitive particle concentrations fold at different times for coordinated multi-component assembly.

4D printing extends additive manufacturing by incorporating time as the fourth dimension, using materials that change shape or properties in response to external stimuli like temperature, humidity, electrical fields, or mechanical stress. These smart materials can self-assemble, deform programmatically, or respond to their environment. For example, materials reacting to temperature (Peltier effect) can change shape when heated or cooled, enabling grippers or adaptive structures. This technology enables objects that detect and respond to their environment, opening possibilities for self-repairing structures, adaptive devices, and responsive systems. The ability to program material behavior transforms manufacturing from creating static objects to producing dynamic, responsive systems.

4D printing extends 3D printing by adding the ability for printed objects to change shape over time. Shape memory materials, such as certain polymers, can be deformed and then return to their original programmed shape when exposed to specific conditions like heat. These materials 'remember' their original configuration and can reshape themselves autonomously without external force.

3D bioprinting is an additive manufacturing technique that fabricates three-dimensional tissue-like structures by layer-by-layer deposition of bioinks containing living cells and biomaterials, while 4D bioprinting extends this capability by incorporating stimuli-responsive materials that can change shape or function in response to external triggers such as temperature, magnetic fields, electric fields, or light, enabling the creation of dynamic, patient-specific tissue constructs for regenerative medicine applications.

Translating bio-printing technology to clinical practice faces multiple barriers: the need for multidisciplinary teams combining expertise in computer science, chemistry, cell biology, and mechanical engineering; the absence of clinically certified bio-printers for medical use; and complex regulatory frameworks that create high barriers to entry. The regulatory environment, designed for traditional medical products, creates challenges for bio-printed tissues that may not fit existing categories. Additionally, the technology requires significant investment (5-10 years) that both academic research and industry may be reluctant to provide. Emerging applications include beta-cell replacement for diabetes treatment, where researchers have created insulin-producing cells responsive to glucose concentration that can be transplanted under the kidney capsule. Hair follicle regeneration represents another promising application, with stem cells grown in specialized bioreactors and implanted using robotic systems.

Bioink composition varies by tissue type: collagen type I for skin, gelatin, alginic acid, synthetic polymers, and biodegradable materials. Cell culture medium contains nutrients and growth factors (insulin, hydrocortisone, EGF) supporting cell survival. For engineered skin: cell expansion takes one week, tissue reconstruction and maturation takes 14 days, with cells differentiating into stratified layers. The outermost stratum corneum provides barrier functions. Tissue engineering faces significant ethical challenges: managing public expectations (technology is often perceived as ready for immediate clinical applications but significant challenges remain for complex organs), cell source limitations (obtaining sufficient cells requires invasive procedures, stem cells carry tumor risks), social stratification (expensive technology may limit access to wealthy individuals), intellectual property concerns about patenting organs and potential illegal organ trading, and regulatory classification challenges (engineered tissues don't fit neatly into existing categories). Major medical centers are developing programs integrating research and clinical applications.

This section addresses the translation of bioprinted technologies from laboratory to clinical application. Bioprinted cardiac conduits have been implanted in mice by suturing directly into the inferior vena cava, achieving 100% patency and progressive vascularization over 6 months. Ultrasound tracking shows intrinsic beating and neo-tissue remodeling with proper sarcomere structure. The section discusses clinical pathways, noting the first FDA-approved trial for 3D bioprinted ear implantation occurred in 2022, with expectations for acellular scaffolds entering clinical trials soon. For solid organs, phase I/II trials are projected for early 2030s, with widespread availability anticipated in 10-15 years. The section addresses immunological challenges through universal donor cells using hypoimmune iPSCs, which would expand patient populations benefiting from therapy while avoiding severe side effects of immunosuppressive drugs. Regulatory and reimbursement challenges are discussed, including FDA approval complexities for combination devices and the need for new payment mechanisms for novel therapies.

As bioprinting advances toward clinical translation, critical questions emerge regarding ethical frameworks, regulatory compliance, and practical implementation. Key ethical considerations include informed consent protocols, distinctions between tissue restoration versus enhancement, and debates surrounding stem cell sources (embryonic cells raising embryo destruction concerns versus induced pluripotent cells carrying teratoma risks). Organ fabrication faces unique challenges: multi-cell type printing requires sophisticated multi-nozzle systems; vascularization and innervation remain unsolved problems; current approaches often rely on single-cell seeding followed by co-culturing. While electrospinning suits thin patches (cardiac, neural), whole organs demand 3D bioprinting capabilities. The ultimate vision—a 'pharmacy for organs' providing patient-specific tissues—requires overcoming technical barriers in vascularization, innervation, and multi-material printing. Research continues exploring magnesium-based scaffolds for vascularized bone applications, representing incremental progress toward functional organ replacement therapies.

Before biofabrication reaches routine clinical use, three major challenges must be overcome. First, vascularization—the creation of internal blood supply networks—is essential because all tissues require blood connections for nutrient delivery and waste removal. Engineers are developing 3D printers capable of fabricating intricate tube networks throughout constructs, where cells develop into blood vessels, and the supporting material is subsequently removed. Second, regulatory frameworks for medical devices have not yet accommodated 3D printed constructs containing patient-derived biological materials, creating jurisdictional gaps that require collaboration between researchers, medical device companies, policymakers, and legal experts. Third, ethical considerations arise regarding human enhancement: if biofabrication enables creating superior organs beyond natural human capabilities—such as lungs with enhanced oxygen capacity, unbreakable bones, or hearts that never fail—society must determine how to define human identity and whether improving upon nature constitutes acceptable medical practice. These interconnected technical, regulatory, and ethical challenges will shape the future trajectory of biofabrication technology.